Relationship between miRNA profiles and oncogenes mutations in non-smokers lung cancer. Relevance for lung cancer personalized screenings and treatments
| Autor: | Alberto, Izzotti, Gabriela Coronel Vargas, Alessandra, Pulliero, Simona, Coco, Irene, Vanni, Cristina, Colarossi, Giuseppina, Blanco, Agodi, ANTONELLA PAOLA, Barchitta, Martina, Maugeri, ANDREA GIUSEPPE, CT-ME-EN Cancer Registry Workers, OLIVERI CONTI, GEA MARZIA, Ferrante, Margherita, Sciacca, Salvatore |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
nonsmokers lung cancer
miRNA environmental risk factors oncogenes mutations lcsh:Medicine Medicine (miscellaneous) medicine.disease_cause Article 03 medical and health sciences 0302 clinical medicine microRNA Blood plasma medicine Lung cancer 030304 developmental biology 0303 health sciences Mutation Oncogene business.industry lcsh:R Cancer medicine.disease 030220 oncology & carcinogenesis Cancer research Mutation testing Carcinogenesis business |
| Zdroj: | Journal of Personalized Medicine, Vol 11, Iss 182, p 182 (2021) Journal of Personalized Medicine Volume 11 Issue 3 |
| Popis: | Oncogene mutations may be drivers of the carcinogenesis process. MicroRNA (miRNA) alterations may be adaptive or pathogenic and can have consequences only when mutation in the controlled oncogenes occurs. The aim of this research was to analyze the interplay between miRNA expression and oncogene mutation. A total of 2549 miRNAs were analyzed in cancer tissue—in surrounding normal lung tissue collected from 64 non-smoking patients and in blood plasma. Mutations in 92 hotspots of 22 oncogenes were tested in the lung cancer tissue. MicroRNA alterations were related to the mutations occurring in cancer patients. Conversely, the frequency of mutation occurrence was variable and spanned from the k-ras and p53 mutation detected in 30% of patients to 20% of patients in which no mutation was detected. The prediction of survival at a 3-year follow up did not occur for mutation analysis but was, conversely, well evident for miRNA analysis highlighting a pattern of miRNA distinguishing between survivors and death in patients 3 years before this clinical onset. A signature of six lung cancer specific miRNAs occurring both in the lungs and blood was identified. The obtained results provide evidence that the analysis of both miRNA and oncogene mutations was more informative than the oncogene mutation analysis currently performed in clinical practice. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|